Fair Value Measurements - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Mar. 31, 2024	Dec. 31, 2023	May 03, 2023	Mar. 31, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Payments related to the settlement of the contingent consideration liability, Financing activities			$ 142	$ 3,434
Payments related to the settlement of the contingent consideration liability, Operating activities			100	12,700
Impairment of equity method investment			0
Impairment of intangible assets			0	0
Interest income	$ 7,561	$ 221	14,837	352
Investments in privately held companies	22,600		22,600			$ 19,100
Long-term notes receivable, net	8,700		8,700			3,200
Long-term notes receivable issued			6,200
Allowance for expected credit losses	1,406	$ 296	1,406	296	$ 1,388	568		$ 290	$ 281
Solo Pace
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term notes receivable issued			1,500
Fluidx
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Ownership percentage					19.90%
Long-term notes receivable issued			3,000
Bluegrass Vascular Technologies, Inc
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of equity method investment				$ 300
Ownership percentage							19.50%
Equity method investment							$ 245
Selio
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term notes receivable issued			1,700
Allowance for expected credit losses	1,400		1,400			600
Other long-term obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability, noncurrent	3,000		3,000			3,000
Accrued expenses
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability, current	$ 400		$ 400			$ 400